SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-22-000019
Filing Date
2022-02-07
Accepted
2022-02-07 16:03:07
Documents
12
Period of Report
2022-02-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20220202.htm   iXBRL 8-K 42129
  Complete submission text file 0001479290-22-000019.txt   179601

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20220202.xsd EX-101.SCH 1937
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20220202_lab.xml EX-101.LAB 24137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20220202_pre.xml EX-101.PRE 12542
6 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20220202_htm.xml XML 11389
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 22597378
SIC: 2834 Pharmaceutical Preparations